Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Luzietoso (PARIS CEDEX 18, France), M. Ghanem (PARIS CEDEX 18, France), P. Le Guen (PARIS CEDEX 18, France), C. Taillé (PARIS CEDEX 18, France). Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study.. 2258

Member's Comments

No comment yet.

Related content which might interest you: Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020 Year: 2020 Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021 Year: 2022 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Mepolizumab is effective in severe eosinophilic asthmatics: an Austrian real-life study. Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Omalizumab versus mepolizumab in severe asthma: a propensity score matched efficiency retrospective cohort study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Development of asthma in patients with eosinophilic bronchitis: prospective follow up study Source: Eur Respir J 2002; 20: Suppl. 38, 51s Year: 2002 A weight-based exacerbation dose-response analysis of mepolizumab in severe asthma with eosinophilic phenotype Source: International Congress 2016 – Asthma management Year: 2016 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008